Search > Results
You searched for: EV180020 (EV-TRACK ID)
Showing 1 - 3 of 3
Showing 1 - 3 of 3
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV180020 | 1/3 | Homo sapiens | Blood plasma |
(d)(U)C SEC |
Gámez-Valero, Ana | 2019 | 28% | |
Study summaryFull title
All authors
Ana Gámez-Valero, Jaume Campdelacreu, Dolores Vilas, Lourdes Ispierto, Ramón Reñé, Ramiro Álvarez, M. Pilar Armengol, Francesc E. Borràs & Katrin Beyer
Journal
Translational Neurodegeneration
Abstract
Background
Because of the increasing life expectancy in our society, aging-related neurodegenerative (show more...)
EV-METRIC
28% (59th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Dementia with Lewy Bodies
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
SEC Protein markers
EV: CD9/ CD63/ CD81/ CD5L
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Pelleting performed
No
Size-exclusion chromatography
Total column volume (mL)
15
Sample volume/column (mL)
2
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Nanodrop Abs 280 nm
Characterization: RNA analysis
Database
Yes
Proteinase treatment
No
RNAse treatment
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
PMID previous EV particle analysis
Electron microscopy
Extra particle analysis
NTA
Report type
Modus
Reported size (nm)
127
EV concentration
Yes
Particle yield
110000000000
EM
EM-type
Cryo-EM
Image type
Close-up
|
||||||||
EV180020 | 3/3 | Homo sapiens | Blood plasma |
(d)(U)C SEC |
Gámez-Valero, Ana | 2019 | 28% | |
Study summaryFull title
All authors
Ana Gámez-Valero, Jaume Campdelacreu, Dolores Vilas, Lourdes Ispierto, Ramón Reñé, Ramiro Álvarez, M. Pilar Armengol, Francesc E. Borràs & Katrin Beyer
Journal
Translational Neurodegeneration
Abstract
Background
Because of the increasing life expectancy in our society, aging-related neurodegenerative (show more...)
EV-METRIC
28% (59th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
SEC Protein markers
EV: CD9/ CD63/ CD81/ CD5L
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Pelleting performed
No
Size-exclusion chromatography
Total column volume (mL)
15
Sample volume/column (mL)
2
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Nanodrop Abs 280 nm
Characterization: RNA analysis
Database
Yes
Proteinase treatment
No
RNAse treatment
No
Characterization: Lipid analysis
No
PMID previous EV particle analysis
Electron microscopy
Extra particle analysis
EM
EM-type
Cryo-EM
Image type
Close-up
|
||||||||
EV180020 | 2/3 | Homo sapiens | Blood plasma |
(d)(U)C SEC |
Gámez-Valero, Ana | 2019 | 14% | |
Study summaryFull title
All authors
Ana Gámez-Valero, Jaume Campdelacreu, Dolores Vilas, Lourdes Ispierto, Ramón Reñé, Ramiro Álvarez, M. Pilar Armengol, Francesc E. Borràs & Katrin Beyer
Journal
Translational Neurodegeneration
Abstract
Background
Because of the increasing life expectancy in our society, aging-related neurodegenerative (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Alzheimer's disease
Focus vesicles
extracellular vesicle
Separation protocol
Separation protocol
(d)(U)C
SEC Protein markers
EV: CD9/ CD63/ CD81/ CD5L
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 10,000 g and 50,000 g
Pelleting performed
No
Size-exclusion chromatography
Total column volume (mL)
15
Sample volume/column (mL)
2
Resin type
Sepharose CL-2B
Characterization: Protein analysis
Protein Concentration Method
Nanodrop Abs 280 nm
Characterization: RNA analysis
Database
Yes
Proteinase treatment
No
RNAse treatment
No
Characterization: Lipid analysis
No
|
||||||||
1 - 3 of 3 |
EV-TRACK ID | EV180020 | ||
---|---|---|---|
species | Homo sapiens | ||
sample type | Blood plasma | ||
condition | Dementia with Lewy Bodies | Control condition | Alzheimer's disease |
separation protocol | (d)(U)C SEC | (d)(U)C SEC | (d)(U)C SEC |
Exp. nr. | 1 | 3 | 2 |
EV-METRIC % | 28 | 28 | 14 |